Stock Analysis of Akari Therapeutics PLC (AKTX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code AKTX
Close 1.52
Change 0.0400 / 2.70 %
Volume 20155.00
Vol Change 13198.00 / 189.71 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Akari Therapeutics PLC
PE (TTM)

-19217.61

Very Poor
Price / Book

345.23

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

12044.02 K

Enterprise Value

8199.02 K

ROA (TTM)

-0.622

Very Poor
ROE (TTM)

-1.80

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

43.61 %

-10008.00 K
Debt to Equity

0

Excellent
Altman Z Score

-84.28

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.839

Not Good


Highs/Lows of Akari Therapeutics PLC
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.6 5.00 % 1.54 % 1.721.410116-May-2414-May-24
Two Week1.36 11.76 % 3.42 % 1.751.170109-May-2406-May-24
One Month1.1212 35.57 % 5.60 % 1.86761.080502-May-2419-Apr-24
Three Month2.24 32.14 % 5.95 % 2.441.077504-Mar-2417-Apr-24
Six Months3.2 52.50 % 17.48 % 3.48721.077520-Nov-2317-Apr-24
One year4.244 64.18 % 27.52 % 5.51.077507-Aug-2317-Apr-24
Two year21.4 92.90 % 29.70 % 13.41.077507-Oct-2217-Apr-24
Five year55.2 97.25 % 85.46 % 11.00.140609-Jan-2309-Jun-23
Ten year1030.0 99.85 % 182.41 % 1400.00.140618-Jun-1409-Jun-23


Technical View of Akari Therapeutics PLC
RSI

52.70

Neutral
MACD

0.0067

Bullish
ADX

32.18

Mild Bullish
Super Trend

1.22

Mild Bullish
Williams %R

-49.84

Neutral
CCI

57.06

Neutral


EMA 5

1.50

Bullish
EMA 15

1.46

Mild Bullish
EMA 50

1.62

Mild Bearish
EMA 100

2.02

Mild Bearish
SMA 100

2.09

Mild Bearish
SMA 200

2.84

Strong Bearish
SMA 5 / 20

1.49 / 1.41

Bullish
SMA 15 / 50

1.48 / 1.55

Mild Bearish
SMA 50 / 200

1.55 / 2.84

Strong Bearish




Charts of Akari Therapeutics PLC


Returns of Akari Therapeutics PLC with Peers
Period / StockAKTXOTRKLIFWCMMB
1 Week-5.00%-6.90%-11.10%0.238%
1 Mth35.57%-30.21%-18.80%42.54%
3 Mth-32.14%34.99%-6.61%33.51%
6mth-52.50%-58.20%-88.60%47.75%
1 Year-64.18%-90.34%-93.74%-53.28%
2 Year-92.90%-97.46%--71.68%
5 Years-97.25%-99.77%--99.94%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Akari Therapeutics PLC with Peers
Ratio / StockAKTXOTRKLIFWCMMB
PE-19217.61-0.145-0.078-2.82
P/B345.230.7790.00222.78
ROA-0.622-150.15-1.57-76.13
ROE-1.80-538.47-29.44-98.68
Debt To Equity00.1072.490.0045
Revenue0
% 		11714.00 K
19.29 % 		8377.00 K
64.23 % 		0
%
Net Income-10008.00 K
43.61 % 		-30630.00 K
49.39 % 		-36356.00 K
390.17 % 		-24158.59 K
12.61 %


Technicals of Akari Therapeutics PLC with Peers
Technical / StockAKTXOTRKLIFWCMMB-
ADX32.1831.1321.6018.45
CMF0.0490-0.142-0.1470.092
MFI64.3354.6514.2379.82
RSI52.7043.8038.2156.30
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Akari Therapeutics PLC

Address : 75/76 Wimpole Street, London, United Kingdom, W1G 9RT
Tel : 44 20 8004 0270
URL : https://www.akaritx.com
Code : AKTX, ISIN : US00972G1085, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 21_Sep_2015
Employee Count : 9

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)